Article info

PDF

Original research article
Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction

Authors

  1. Correspondence to Rola Haroun, Novartis Pharma AG, Postfach, CH-4002 Basel, Switzerland; Rola.Haroun{at}novartis.com
View Full Text

Citation

McMurray JJV, Trueman D, Hancock E, et al
Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction

Publication history

  • Received September 22, 2016
  • Revised October 25, 2017
  • Accepted November 2, 2017
  • First published December 21, 2017.

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.